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Summary
 
Complement receptor type 3 (CR3, CD11b/CD18) serves as a receptor for a number of en-
dogenous ligands and infectious organisms, and is involved in adhesion and host defense func-
tions. Here, we report that signaling via CR3 plays an important role in regulating production
of interleukin-12 (IL-12), a key mediator of cell-mediated immunity (CMI). We demonstrate
with a variety of stimuli a dose-dependent, specific downregulation of IL-12 secretion by hu-
man monocytes in vitro
 
 
 
after
 
 
 
exposure to antibodies to CR3 (anti-CD11b and anti-CD18), as
well as to the natural CR3 ligands, iC3b, and 
 
Histoplasma capsulatum
 
. CR3 antibodies also sup-
pressed interferon-
 
g
 
 (IFN-
 
g
 
) production in cultures of human peripheral blood mononuclear
cells (PBMC). We determined that one mechanism by which CR3 antibodies may suppress
IL-12 production is by the inhibition of IFN-
 
g
 
–induced tyrosine phosphorylation. Finally, in a
murine model of IL-12–dependent septic shock, we provide evidence that administration of
CR3 antibodies leads to suppression of IL-12 and IFN-
 
g
 
 in vivo. Our studies thus define a
novel role for CR3 in regulating CMI functions via IL-12.
 
C
 
R3 is a heterodimeric molecule which, like LFA-1
(CD11a/CD18) and CR4 (CD11c/CD18), belongs to
the 
 
b
 
2
 
-integrin family of cell adhesion molecules (1–5). CR3
is expressed mainly on polymorphonuclear leukocytes, mono-
cytes and macrophages, and natural killer cells (1, 2), and
interacts with a variety of ligands including complement
fragment iC3b, intercellular adhesion molecule 1 (ICAM-
1)
 
1
 
, fibrinogen, and 
 
b
 
-glucan (2, 4).
 
 
 
Moreover, it mediates
the binding of opsonized or unopsonized infectious agents
such as
 
 Histoplasma capsulatum, Leishmania major, 
 
group B
streptococci
 
, Bordetella pertussis, Candida albicans
 
, and several
mycobacteria (2, 5–7).
Previous studies have shown that CR3 is involved in
several monocyte and macrophage functions including trans-
migrational adhesion (2, 4, 8),
 
 
 
phagocytosis, nitric oxide
production and the generation of a respiratory burst (2, 3,
5, 8, 10). In addition, CR3 signaling may indirectly affect
T cell function as the administration of antibodies to CR3
to animals suppresses delayed type hypersensitivity (DTH)
reactions (11, 12),
 
 
 
and fatally potentiates infections with
 
Listeria monocytogenes
 
 or 
 
Toxoplasma gondii 
 
(13, 14)
 
. 
 
Since
these phenomena are dependent on an intact cell-mediated
immunity (CMI) and Th1 responses, we explored the role
of CR3 signaling in regulating cytokines that mediate such
responses.
 
Materials and Methods
 
Cell Isolation, Cell Culture Conditions and Assessment of Cytokine
Production.
 
Human monocytes were obtained from healthy do-
nors (total 
 
n
 
 
 
5
 
 14) by standard leukapheresis and were highly pu-
rified (95–99%) by counterflow centrifugal centrifugation (15).
Cell purity was checked by flow cytometry analysis using mono-
clonal antibodies to CD14 and CD11b (Becton Dickinson, San
Jose, CA). Monocytes were cultured at 2 
 
3
 
 10
 
6
 
 cells/ml for 24 h
in 1 ml of RPMI 1640 medium (Whittaker, Walkersville, MD)
supplemented with 10% fetal calf serum (Whittaker), 100 
 
m
 
g/ml
penicillin, 100 
 
m
 
g/ml streptomycin and 0.03% glutamine and
stimulated at the beginning of the culture with the following sub-
stances as indicated: heat-killed, formalin-fixed 
 
Staphylococcus
 
 
 
au-
reus
 
, Cowan I strain (SAC; Calbiochem, Cambridge, MA), LPS
(
 
Escherichia coli
 
 serotype 0127:B8; Sigma Chem. Co., St. Louis,
MO) (16, 17), recombinant IFN-
 
g
 
 (Genzyme, Cambridge, MA),
CD40L trimer (kindly provided by Immunex Corporation, Seat-
tle, WA), IFN-
 
a
 
 (Endogen, Cambridge, MA), or anti–IFN-
 
g
 
(Endogen). One experiment was typically performed with the
monocytes from one donor, and there was individual variability
in IL-12 production (e.g., range for SAC plus IFN-
 
g
 
 stimulation
380–3,300 pg/ml IL-12 p70, mean 
 
z
 
1,750 pg/ml). Monocytes
were incubated with heat-killed 
 
Histoplasma
 
 
 
capsulatum
 
 (HC),
(strain GS-57, kindly provided by Dr. R. Seder, Lymphokine
Regulation Unit, LCI, NIAID, NIH) or iC3b-SRBC (2 
 
3
 
 10
 
7
 
/ml)
2 h before stimulation as indicated. iC3b-SRBC were prepared
 
1
 
Abbreviations used in this paper:
 
 CMI, cell-mediated immunity; DTH, de-
layed type hypersensitivity; ECL, enhanced chemiluminescence; HC,
 
Histoplasma capsulatum
 
; HRP, horseradish peroxidase; ICAM-1, intercel-
lular adhesion molecule 1; LPG, lipophosphoglycan; SAC, 
 
Staphylococcus
aureus
 
 cells; STAT1, signal transducers and activators of transcription 1.
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by sequential addition of anti-sheep erythrocyte antibodies (IgM;
PharMingen, San Diego, CA) and C5-deficient human serum
(Sigma) to SRBC as described (18, 19).
 
 
 
The presence of iC3b on
the cell surface was verified by flow cytometry showing a 
 
.
 
100-
fold increase in fluorescence intensity with a monoclonal anti-
body to the iC3b neoantigen (Quidel, San Diego, CA). Human
PBMC were isolated by Ficoll-Hypaque density gradient centrif-
ugation from leukocyte concentrates prepared by automated leu-
kapheresis of healthy donors (total 
 
n
 
 
 
5
 
 5) as described (15).
PBMC were cultured similar to monocytes, except that they
were cultured at 1
 
 3 
 
10
 
6
 
 cells/ml for 48h and stimulated with
PHA (Sigma). In some experiments, recombinant human IL-12,
or recombinant IL-2 (PharMingen) were added as indicated.
Culture supernatants were assessed in duplicate by ELISA us-
ing kits or antibody pairs for IL-12 p70, TNF-
 
a
 
 (both from
R&D Systems), IL-12 p40, IL-10 (both from PharMingen), IL-6,
IL-1
 
b
 
, IFN-
 
a
 
, IFN-
 
g
 
 (all from Endogen, Cambridge, MA), and
TGF-
 
b
 
1 (Genzyme). Unstimulated cultures (with or without
added integrin antibodies) contained cytokines below the detec-
tion limit (IL-12 p70 
 
.
 
5 pg/ml, IL-12 p40 
 
.
 
20 pg/ml, IFN-
 
a
.
 
10 pg/ml, IL-10 
 
.
 
100 pg/ml, TGF-
 
b
 
 
 
.
 
50 pg/ml, IL-6 
 
.
 
50
pg/ml, IL-1
 
b
 
 
 
.
 
25 pg/ml). For TNF-
 
a
 
, the detecting limit was
 
.
 
25 pg/ml and the background was below 200 pg/ml. Integrin
antibodies were added at the beginning of the culture at the in-
dicated concentrations and were obtained in a preservative-free
preparation or dialyzed overnight before use. The antibodies and
monocyte stimulants (e.g., CD40L trimer) contained low endo-
toxin levels as per information by the manufacturer and as dem-
onstrated in appropriate assays performed in the presence of 1–5
 
m
 
g/ml of polymyxin B (Sigma) which revealed little or no effect
on IL-12 and TNF-
 
a
 
 production. Antibodies were bound to
plastic culture plates by overnight incubation at 10 
 
m
 
g/ml in 100
 
m
 
l of carbonate buffer at 4
 
8
 
C followed by washing with PBS, and
bound to polystyrene beads (goat anti–mouse IgG, Dynabeads
M450, Dynal, Lake Success, NY) according to the manufacturer’s
instructions. L cells stably transfected with a plasmid expressing
the Fc
 
g
 
RII receptor (CD32) as previously described (20, 21)
were incubated with 10 
 
m
 
g/ml of antibody at 37
 
8
 
C for 1 h,
washed, and then used for the assays. Integrin antibodies were
obtained from the American Type Culture Collection (ATCC,
Rockville, MD; clone LM2/1 [18]; murine IgG1; and clone M1/
70, rat IgG2b), Monosan (Amsterdam, Netherlands; clone MEM-
48, murine IgG1), PharMingen (clones G43-25B, murine IgG2b,
B-ly6, murine IgG1, 44, murine IgG1, 107.3, murine IgG1,
G555-178, murine IgG2a), Becton Dickinson (clone D12, mu-
rine IgG2a), and Caltag (San Francisco, CA; clone CLB-LFA-1/1,
murine IgG1).
 
Western Blotting.
 
Human monocytes (2.5
 
 3 
 
10
 
7
 
 in 5 ml per
condition) were either untreated, treated with anti-CR3 (clone
LM2/1, 10 
 
m
 
g/ml) for 20 min, treated with recombinant IFN-
 
g
 
(1 
 
m
 
g/ml) for 5 min, or treated with LM2/1 for 20 min followed
by IFN-
 
g
 
 for 5 min. Cells were then solubilized in a buffer con-
sisting of 1% Triton X (Pierce Chem. Co., Rockford, IL), 150
mM NaCl, 50 mM Tris, pH 8.0, 50 mM Na-pyrophosphate, 2.5
mM aprotinin, 2.5 mM leupeptin, 1 mM phenylmethylsulfonyl
fluoride, and 1 mM NaVO
 
3 
 
(all from Sigma). Protein concentra-
tion of the cell lysates was estimated by measuring the optical
density at 280 nm based on the assumption that optical density of
1.4 corresponds to 1 mg/ml. Cell lysates were analyzed using
Tris-glycine gels (Novex, San Diego, CA) with equivalent amounts
of protein loaded in each lane, followed by transfer to nitrocellu-
lose membranes (Schleicher and Schuell, Keene, NH). After over-
night blocking in 5% nonfat dry milk, 150 mM NaCl, 50 mM Tris,
and 0.05% Tween 20, membranes were incubated with horserad-
ish peroxidase (HRP)-conjugated phosphotyrosine antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA) for 2 h. Membranes
were then washed and developed with enhanced chemilumines-
cence (Super-signal
 
Ô
 
 substrate; Pierce). Cell lysates from epider-
mal growth factor–stimulated A431 cells (Upstate Biotechnology
Incorporation, Lake Placid, NY) served as positive control for
phosphotyrosine and STAT1 (signal transducers and activators of
transcription) expression. For reprobing, membranes were stripped
in 0.2 M glycine buffer (pH 2.8) for 30 min, washed, exposed to a
rabbit polyclonal antibody to STAT1 (Santa Cruz), washed again,
incubated with a donkey anti–rabbit HRP-conjugated antibody
(Amersham Corp., Arlington Heights, IL), and developed with en-
hanced chemiluminescence.
 
Treatment of Animals, LPS Challenge, and Detection of Cytokine
Levels.
 
6–10-wk-old BALB/c mice housed under standard con-
ditions were treated intraperitoneally with 0.5 ml of PBS contain-
ing either rat IgG (1 mg per mouse; Sigma), antibodies to CR3 (1
mg of clone M1/70 or 0.5 mg of 5C6; Biosource International,
Camarillo, CA), or anti–IL-12 (1 mg, clone C17.8, the hybri-
doma for which was kindly provided by Dr. G. Trinchieri, The
Wistar Institute, Philadelphia, PA). This treatment was followed
1 h later by an intravenous (tail vein) injection of LPS (1 
 
m
 
g per
mouse in 100 
 
m
 
l of PBS) or PBS alone, and mice were then ei-
ther killed either 3 h (for determination of IL-12 p40) or 6 h (for
IL-12 p70 and IFN-
 
g
 
) later by cervical dislocation after blood had
been obtained by cardiac puncture. Serum was obtained after 30
min clotting of the blood at 37
 
8
 
C and subsequent centrifugation.
Serum levels of IL-12 (p40 and p70) and IFN-
 
g
 
 were assessed by
ELISA using antibody pairs from PharMingen. Injection of
higher doses of anti-CR3 (e.g., 1 or 3 mg M1/70 per mouse at
12 h and/or 1 h before LPS challenge) had no additional suppres-
sive effects on IL-12 or IFN-
 
g
 
 secretion
 
.
 
 IL-12 p70 and IFN-
 
g
 
were not detectable in mice that had received only PBS and were
very low or undetectable at three hours after LPS administration
or in anti–IL-12–treated mice (data not shown).
 
Stastitics.
 
Statistical significance of differences was determined
by the Student’s 
 
t
 
 test where indicated.
 
Results and Discussion
 
In initial studies we determined whether antibodies to
CR3 affect the secretion of IL-12 by highly purified hu-
man monocytes stimulated with 
 
Staphylococcus aureus
 
 cells
(SAC) and IFN-
 
g
 
. We found that exposure of monocytes
to monoclonal antibodies that bind to the functionally im-
portant I domain of CD11b (clone LM2/1) (18) or to CD18
results in a dose dependent and profound reduction of IL-12
(p70 heterodimer and p40 monomer) secretion, whereas
antibodies to CD11a had no effects (Fig. 1, 
 
A
 
 and 
 
B
 
). Sim-
ilarly, addition of one clone of CD11c antibodies had only
modest effects on IL-12 production (Fig. 1, 
 
A
 
 and 
 
B
 
).
These cytokine protein levels correlated with downregu-
lated messenger RNA levels for IL-12 p35 and p40 as de-
termined by reverse-transcriptase PCR (data not shown)
 
.
 
The blockade of IL-12 production was observed with a va-
riety of monocyte stimulants known to induce IL-12 (e.g.,
IFN-
 
g
 
 in combination with LPS, SAC or CD40L trimer,
Figs. 1, 
 
D
 
 and 
 
E
 
 and 2, 
 
A–C
 
) and with a panel of mono-
clonal antibodies to CR3 (Table 1). In contrast, secretion 
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of other monocyte products such as TNF-
 
a
 
, IL-10, TGF-
 
b
 
,
IL-6, and IL-1
 
b 
 
(Fig. 1 
 
C
 
; Table 1) was not significantly al-
tered by any of the above antibodies (as determined in the
same cultures), nor was cell viability (trypan blue exclusion) or
cell surface expression of CD14 (flow cytometry; data not
shown).
 
 
 
The one exception was an anti-CR3–induced re-
duction of IFN-
 
a 
 
secretion (Table 1), a macrophage-derived
cytokine previously shown to enhance IL-12–induced Th1
development (22). It is interesting to note that with higher
doses of CD11b antibodies (25 mg/ml), we observed a further
downregulation of IL-12 (,5 pg/ml) and a twofold increase
in IL-6 (5,450 pg/ml), a cytokine dichotomy previously
described in individuals with HIV infection (23).
We then studied the ability of natural CR3 ligands to
suppress IL-12 production by using iC3b-coated sheep red
blood cells (iC3b-SRBC) and heat-killed Histoplasma capsu-
latum (HC), an organism that binds to CR3 (3, 24). Similar
to our findings with anti-CD11b, when human monocytes
were incubated with iC3b-SRBC or heat-killed HC and
subsequently stimulated with IFN-g and either SAC, LPS,
or CD40L trimer, we observed a downregulation of IL-12
p70 production (Figs. 3 and 4 A), whereas TNF-a and
IL-10 levels were largely unaffected (Fig. 4 B). The inhibi-
tion of IL-12 production by HC was: (a) not due to direct
suppression by IL-10, since the addition of anti–IL-10 anti-
bodies (10 mg/ml) to the cultures only slightly increased
Figure 1. Effects of various integrin antibodies on secretion of IL-12 and other cytokines by human monocytes. (A–C) Production of (A) het-
erodimeric IL-12 (p70) and (B) monomeric IL-12 (p40) in cultures of highly purified human monocytes as determined by ELISA is suppressed by anti-
bodies to CD11b and CD18 in a dose dependent manner, but not by anti-CD11a and modestly by anti-CD11c, when stimulated with SAC (0.01%) and
IFN-g (1 mg/ml). Secretion of TNF-a (C) in the same culture supernatants is not altered by such antibodies. Data in A–C represent means of duplicates
from one experiment and are representative of five experiments. (D and E) Suppression of IL-12 p70 by anti-CD11b (clone LM2/1) in a dose-depen-
dent fashion after stimulation with LPS (1 mg/ml) plus IFN-g (1 mg/ml) and CD40L trimer (3 mg/ml) plus IFN-g (1 mg/ml). One of three experiments
is shown.1990 CR3 and IL-12 Production
the levels of IL-12; and (b) was related to the ability of HC
to bind to b2 integrins, since the addition of a CD18 anti-
body (clone CLB LFA1/1 which did not directly inhibit
IL-12 production, see Table 1) to these cultures partially
reversed the suppressive effect of HC (threefold increase in
IL-12 p70, i.e., to 40% of levels without HC).
Our findings with iC3b-SRBC expand upon a recent
study by Karp et al. (25), who first demonstrated a role for
complement regulatory proteins in the regulation of IL-12.
It was shown that the in vitro infection of human mono-
cytes with measles virus results in the suppression of IL-12
production and that such suppression was mediated through a
measles virus receptor, CD46, which is an important com-
plement regulatory protein that binds C3b (25). Thus, it
appears that the binding of C3b to CD46, and the binding
of iC3b to CR3, as may occur with the interaction of op-
sonized organisms with phagocytes, are two mechanisms by
which complement components may suppress IL-12 pro-
duction by human monocytes.
The suppression of IL-12 production by antibodies and
ligands to CR3 could be due either to the transmission of a
direct inhibitory signal through the CR3 molecule, or to
Figure 2. Monocytic IL-12 production induced by various stimuli is suppressed by antibodies to CD11b. Secretion of IL-12 as determined by ELISA
in cultures of human monocytes after stimulation with (A) LPS and IFN-g, (B) SAC and IFN-g, and (C) LPS alone (1 mg/ml), SAC alone (0.01%), SAC
plus anti–IFN-g (10 mg/ml), SAC plus IFN-a (10 ng/ml), and CD40L trimer (3 mg/ml) plus IFN-g (1 mg/ml). Similar results were obtained with LPS
plus increasing doses of IFN-g, SAC plus increasing doses of IFN-g, SAC plus TNF-a, TNF-a, and SAC plus anti–IL-10 (data not shown). One of three
experiments is shown.
Table 1. Effects of Integrin Antibodies on the Secretion of a Variety of Cytokines by Highly Purified Human Monocytes
Cytokine None
Isotype control
CD11b
CD18
CD11a CD11c
IgG1
(clone 107.3)
IgG2a
(G555-178) (MEM-48)
(CLB-
LFA 1/1) (LM2/1) (44) (M1/70) (D12) (G43-25B) (B-ly6)
pg/ml
IL-12 (p70) 2,180 2,040 2,155 260 735 780 670 185 1,720 1,625 770
IL-12 (p40) 23,450 21,960 19,870 2,400 18,170 13,140 19,350 3,280 21,580 22,200 12,410
IFN-a 250 265 ND 30 130 85 175 15 250 135 240
TNF-a 1,850 2,113 2,325 2,575 2,100 2,638 2,050 1,850 3,188 2,025 3,150
IL-10 5,200 5,750 5,700 4,550 5,500 3,400 4,300 5,500 6,700 4,850 4,950
TGF-b 2,350 2,675 2,375 3,300 2,650 2,275 2,625 3,175 2,950 2,650 2,800
IL-6 2,650 3,050 ND 4,275 3,700 ND 3,450 3,425 3,600 3,350 3,525
IL-1b 2,025 2,138 ND 2,050 2,025 ND 2,363 1,875 2,338 2,200 1,875
Human monocytes (2 3 106/ml) were incubated with the indicated antibodies and stimulated with SAC (0.01%) plus IFN-g (1 mg/ml). Cytokine
levels from culture supernatants were determined as described in Materials and Methods. Data represent antibody concentration of 10 mg/ml. Data
are means of duplicates from one experiment and are representative of three experiments. Percent suppression of IL-12 p70 in all three experiments
was comparable, e.g., percent suppression of IL-12 p70 for clone LM2/1 ranged from 76–98%, for clone 44 (53–74%), for M1/70 (41–78%), for D12
(48–85%), for MEM-48 (82–99%), for CLB LFA1/1 (12–22%), for G43 25B (-16–33%), and for B-ly6 (37–79%). The baseline stimulated IL-12 p70
production varied in the three experiments (i.e., with cells from three different donors) from 1,060 to 2,180 pg/ml. ND denotes not determined.1991 Marth and Kelsall
the blocking of a positive signal for IL-12 production, as
could be provided through interactions between CR3 and
ICAM-1 on neighboring monocytes. To clarify this issue,
we initially performed a number of studies which together
suggested that important cell–cell interactions, especially via
ICAM-1/CR3, are not particularly important for the in-
duction of IL-12, and thus indirectly supported the conclu-
sion that CR3 antibodies act via a direct inhibitory signal.
First, we found that the relative production of IL-12 per
monocyte after SAC and IFN-g stimulation was not al-
tered when cells were diluted over large ranges (>1:1,000)
before culture, i.e., resulting in decreased homotypic interac-
tions (data not shown). Second, the addition of anti–ICAM-1
to monocyte cultures did not suppress IL-12 production
(data not shown). And third, antibodies to CD11b (clone
LM2/1) immobilized onto plastic culture plates, polystyrene
beads coated with anti-mouse IgG (Dynal, Lake Success, NY),
or to FcgRII receptor (CD32)-expressing L cells, com-
pletely inhibited SAC plus IFN-g–induced IL-12 produc-
tion (Fig. 5), suggesting that the membrane-fixed subset of
CR3 (i.e., which remains unbound to the solid supports
[26]) is not capable of providing a positive signal for IL-12
production through an interaction with ICAM-1 on neigh-
boring monocytes.
Because these studies provided only indirect evidence
that anti-CR3 was acting to transmit a negative signal to
monocytes, we next looked more directly for intracellular
targets of inhibitory signaling by CR3. Inhibition of ty-
rosine phosphorylation by CR3 signaling seemed possible
since this effect had been previous demonstrated in a sys-
tem that involves a CR3 ligand. Thus, it has been shown
that tyrosine phosphorylation in response to IFN-g was
suppressed in macrophages infected with L. donovani (27),
an organism binding to monocyte CR3 by either gp63 or
lipophosphoglycan (LPG) (3, 7). Furthermore, a similar
phenomenon has been described in human monocytes after
the binding of immune complexes (28), and a role for b1-
integrin engagement in tyrosine dephosphorylation has been
Figure 3. Inhibition of monocyte IL-12 production by a natural ligand
to CR3, iC3b-coated SRBC. iC3b-SRBC (2 3 107/ml) were incubated
with human monocytes (2 3 106/ml) 2 h before stimulation with LPS (1
mg/ml) plus IFN-g (1 mg/ml), SAC (0.01%) plus IFN-g (1 mg/ml), or
CD40L trimer (3 mg/ml) plus IFN-g (1 mg/ml). IL-10 and TNF-a levels
in the same culture supernatants were not significantly altered (data not
shown). Data are representative of five experiments.
Figure 4. Secretion of IL-12 p70 by monocytes is suppressed by incubation with heat-killed Histoplasma capsulatum (HC). Heat-killed HC at the indicated
concentrations was incubated with human monocytes 2 h before stimulation with LPS (1 mg/ml) plus IFN-g (1 mg/ml), SAC (0.01%) plus IFN-g (1 mg/
ml), or CD40L trimer (3 mg/ml) plus IFN-g (1 mg/ml) (A). (B) IL-10 and TNF-a levels from the same culture supernatants. Data are representative of
five experiments, and percent suppression by HC was similar in all instances.1992 CR3 and IL-12 Production
recently established (29). Thus, we explored the possibility
that reduced production of IL-12 and IFN-a could follow
a CR3-induced inhibition of IFN-g signal transduction. As
shown in Fig. 6, we found that incubation of monocytes
with IFN-g alone induced tyrosine phosphorylation of sev-
eral proteins, one of which was identified as STAT1 (signal
transducers and activators of transcription 1) by Western
blotting with anti-STAT1 antibodies and by use of a posi-
tive tyrosine phosphorylated STAT1 control (Fig. 6). After
preincubation with anti-CR3, IFN-g–induced tyrosine phos-
phorylation of several proteins, including STAT1 was not
seen, suggesting an inhibition of tyrosine phosphorylation,
or alternatively, an accelerated dephosphorylation of ty-
rosine residues by an as yet unidentified protein tyrosine
phosphatase.
The inhibition of IFN-g–mediated STAT1 activation
(i.e., phosphorylation) presents a potential mechanism by
which signaling through CR3 could decrease monocyte
IL-12 production, since there are two potential STAT1-
binding sites (IFN-g activation sequence [GAS] elements)
in the human IL-12 p40 promotor (positions 2127 to
2119 and 2277 to 2268 of the published sequence), and
since mutations with deletions at at least one of these sites
reduced transcription of a reporter gene (30). In addition, it
is possible that the JAK-STAT-GAS signal transduction path-
way may be important for the regulation of human IL-12
p35 gene transcription that is induced by stimulation with
IFN-g (30), or be involved in the expression of gene prod-
ucts that are indirectly responsible for the upregulation of
IL-12 p35 or IL-12 p40 gene transcription or translation.
Finally, the possibility that in addition to its effects on IFN-g
signaling, anti-CR3 suppressed IL-12 production through
an IFN-g–independent mechanism as well was supported
by the observation that the low level of IL-12 induced by
SAC alone, which was unchanged with the addition of anti–
IFN-g, was also inhibited with anti-CR3 (Fig. 2 C). Addi-
tional studies are needed to address these possibilities, as
well as to address whether signaling via CR3 has effects on
transcription factors other than STAT1, such as ets-protein
family members, that have been more directly implicated in
the regulation of IL-12 p40 in humans (30).
We finally extended our studies on functional effects of
CR3 signaling to a murine model of IL-12–dependent sep-
tic shock. In this model, the intravenous injection of LPS
results in symptoms of septic shock as well as high serum
levels of IFN-g and IL-12, all of which can be inhibited by
the systemic administration of anti–IL-12 (31). We chose
this in vivo model to study the effects of the antibodies to
CR3 because, when compared to others, this model should
be much less dependent on cell trafficking. This is because
the injected LPS should be rapidly delivered to all lym-
phoid tissues and the response to LPS is unlikely to depend
on significant migration of cells, at least within the first 3 or
6 h, the times at which we measured IL-12 and IFN-g, re-
spectively. 
Thus, in our studies, BALB/c mice were given intraperi-
toneal injections of either CR3 antibodies (1 mg of clone
M1/70 or 0.5 mg of clone 5C6 [8, 32]) or control rat IgG
1 h before LPS injection and were killed either 3 or 6 h
later, at which time serum was obtained. As shown in Fig.
7, pretreatment with anti-CR3 (clone M1/70) reduced the
serum levels of IL-12 (p40 and p70) by more than 4 and
Figure 5. Monocyte IL-12 production is suppressed by antibodies to
CD11b (clone LM2/1). Antibodies were bound to culture plates, polysty-
rene beads, or L cells as described in Materials and Methods. The secre-
tion of IL-12 was determined by ELISA in cultures of human monocytes
after stimulation with SAC (0.01%) and IFN-g (1 mg/ml). One of three
experiments is shown.
Figure 6. Prevention of IFN-g–induced phosphorylation of STAT1 by
anti-CR3. Human monocytes (2.5 3 107 in 5 ml per condition) were ei-
ther untreated (None), treated with anti-CR3 (LM2/1), treated with re-
combinant IFN-g (IFN-g), or treated with LM2/1 followed by IFN-g
(LM2/1 1 IFN-g). Monocytes were then solubilized and analyzed as de-
scribed in Materials and Methods. Cell lysates from stimulated A431 cells
(A431) served as positive control. The upper panel shows probing of the
nitrocellulose membranes with anti-phosphotyrosine antibodies (a-pTyr)
and the arrow indicates the expression of p91 (STAT1). The lower panel
shows a membrane reprobed with anti-STAT1 (a-STAT1). Data are rep-
resentative of three similar experiments.1993 Marth and Kelsall
2.5-fold, respectively, and similarly diminished the levels of
IFN-g 4-fold. The effects on IL-12 by treatment with M1/
70 (or similar effects seen with clone 5C6; data not shown)
were, consistent with prior studies of these antibodies (8,
13), not due to elimination of circulating leukocytes since
total and differential white blood cell counts were similar in
all treatment groups (data not shown). In addition, we
found that whole spleen cells from anti-CR3–treated and
LPS challenged mice stimulated in vitro with anti-CD3/
anti-CD28 or PHA manifest reduced (two- to fourfold)
IFN-g production when compared to control mice (data not
shown). In accordance with these findings, addition of anti-
CD11b antibodies (10 ml/ml) markedly inhibited IFN-g
production in human monocyte cultures stimulated with
either PHA (3,310 pg/ml IFN-g for isotype control, 1,100
pg/ml for anti-CD11b [LM2/1]), plate-bound anti-CD3
plus anti-CD28 (3,250 pg/ml IFN-g for isotype control,
,10 pg/ml for anti-CD11b) or anti-CD2 plus anti-CD28
(2,450 pg/ml IFN-g for isotype control, ,10 pg/ml for
anti-CD11b), but had no significant effect on cell viability
or on cell proliferation (as determined by [3H]thymidine
incorporation at 72 h). The above effects of anti-CR3 on
IFN-g production were reversed by addition of recombi-
nant human IL-12 (1,100 pg/ml IFN-g after PHA stimula-
tion with anti-CR3, 3,210 pg/ml after addition of 20 ng/
ml of IL-12) but not by IL-2 indicating the specificity for
IL-12.
These data show that the IL-12 response, crucial for the
initiation of most CMI functions (33), may be regulated by
CR3 signaling. Thus, they provide insight into mechanisms
underlying the ability of CR3 antibodies to abolish DTH
reactions (8, 11, 12), to ameliorate Th1 cell–mediated au-
toimmune diseases including antigen-induced arthritis (34)
and experimental allergic encephalomyelitis (35), and to en-
hance the severity of infections with L. monocytogenes (13)
or T. gondii (14). In addition, our studies demonstrating the
inhibition of IL-12 by HC and iC3b-SRBC suggest a
mechanism for the impaired CMI accompanying infections
with CR3 binding microorganisms (e.g., L. major, myco-
bacteria, HIV) (3, 36). In this regard they may provide a
cogent reason for the diminished IL-12 production by
mononuclear cells in HIV infected individuals (17) and in
leishmaniasis (36). It is possible that CR3-induced suppres-
sion of IL-12 responses to the above microorganisms may
result in suppressed monocyte nitric oxide production and
respiratory burst, thereby explaining their ability to thrive
in intracellular compartments.
Finally, our data, together with those recently developed
by Karp et al. (25) showing that suppressed IL-12 in mea-
sles virus infection is mediated by the CD46 complement
regulatory protein, establishes a new locus of control for T
cell–mediated immunity via complement components. Thus,
in disease states as well as in normal responses to invading
microorganisms, signaling through CR3 may play an im-
portant role in regulating Th1–Th2 homeostasis. This is
important for understanding the pathogenesis of infectious
diseases, and may provide a new approach for therapeutic
immunointervention targeting IL-12.
Figure 7. Production of IL-12
and IFN-g in a murine model of
septic shock is suppressed by
treatment with CR3 antibodies.
Pretreatment with 1 mg of anti-
CR3 (clone M1/70) markedly
suppressed the serum levels of
IL-12 p40 and p70 as well as se-
rum levels of IFN-g in BALB/c
mice challenged by intravenous
LPS (1 mg/mouse). Similar re-
sults were obtained with a differ-
ent anti-CR3 antibody (clone
5C6).  Data show the mean 6 SD
of groups consisting of three sep-
arately handled mice. *P ,0.001,
**P ,0.0001, and ***P ,0.05
versus the control (i.e., rat Ig
treated) group as determined by
the Student’s t test. Data are rep-
resentative of five experiments.
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